TheraQuest Biosciences - News

News & Events

Press Releases

2008	8/20/08	TheraQuest Presents Topical Local Anesthetic and Abuse Deterrence Data at the World Congress on Pain
2007	12/18/07	TheraQuest Receives $3 Million in Equity Investment and Licensing Fees from Wonpung
	6/24/07	TheraQuest Announces New Appointments to its Scientific Advisory Board
	6/22/07	TheraQuest Initiates GMP Manufacturing of Abuse Deterrent Sustained Release TQ-1015 Opioid: Novel Kappa Mechanism Reverses Morphine Tolerance
2006	10/26/06	TheraQuest to Present Local Anesthetic Patch Data at Upcoming Rodman & Renshaw 8th Annual Healthcare Conference
	4/18/06	TheraQuest Receives FDA Fast Track Designation for Tramadol ER in Painful HIV-associated Neuropathy
	2/6/06	TheraQuest’s Abuse Deterrent Tramadol ER IND for Neuropathic Pain Accepted by FDA
	1/30/06	TheraQuest Receives 7-Year Market Exclusivity for Topical Capsaicin
2005	8/15/05	TheraQuest to Present Results of Intravenous Ketoprofen Postsurgical Pain Study at the World Congress on Pain in Sydney
	8/11/05	TheraQuest Receives 7-Year Market Exclusivity for Neuropathic Pain Indication for Abuse Deterrent, Once-Daily Tramadol
	7/14/05	TheraQuest To Present New Data on an Abuse Deterrent Strong Opioid at the World Congress on Pain
	4/1/05	TheraQuest Presents TQ-1015 Opioid Inflammatory Pain Results at the American Pain Society Meeting
	3/31/05	TheraQuest Presents Analgesic Synergy Data at U.S. Pain Conference
	3/30/05	TheraQuest Presents Postsurgical Pain Results at the American Pain Society Meeting in Boston
	2/17/05	TheraQuest Receives Orphan Drug Status for its Abuse Deterrent, Once-Daily Tramadol
	2/14/05	TheraQuest Announces a Safer, Abuse Deterrent, Long-acting, Once-Daily Tramadol for Pain Management
	2/8/05	TheraQuest to Present Results on Three Analgesics at the American Pain Society Meeting in Boston
2004	9/10/04	TheraQuest Announces Discovery of Analgesic Synergy with Narcotics
	8/11/04	TheraQuest holds Meetings with FDA, U.K. and Canadian Health Authorities on its Injectable Non-Narcotic Analgesic
	8/4/04	TheraQuest Appoints Scientific Advisory Board and Launches New Corporate Website
	7/22/04	TheraQuest Completes $2.25 Million Seed Round with BioAdvance and Ben Franklin Technology Partners Investments
	2/10/04	BioAdvance Invests More than $3 Million in Regional Life Sciences Enterprises